The calcium-activated protein phosphatase calcineurin is controlled by regulator of calcineurin (RCAN) in organisms ranging from yeast to mammals. Here we performed a yeast two-hybrid screen with RCAN1 as bait, identifying TAK1 binding protein 2 (TAB2) as an interacting partner. TAB2 interacted directly with RCAN1 in vitro and in vivo, recruiting TAK1, TAB1 and calcineurin, forming a macromolecular signalling complex. Overexpression of TAK1 and TAB1, or active TAK1
. Once activated, calcineurin directly dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors within the cytoplasm, promoting their translocation into the nucleus and activation of gene expression 2 . Calcineurin-NFAT signalling is essential in regulating a diverse range of biological processes, including T lymphocyte development and reactivity, development of the nervous and vascular systems, fibre-type switching in skeletal muscle, development of heart valves, development of bone and control of cardiac hypertrophy [1] [2] [3] . Although calmodulin bound to Ca 2+ is the only known activator of calcineurin, a wide range of regulatory proteins have been described that can alter calcineurin activity. One such protein is RCAN (previously known as MCIP/DSCR/calcipressin), which is a member of gene family that includes Rcan1, Rcan2 and Rcan3 4, 5 . In mammalian cells, overexpression of RCAN1 predominantly blocks NFAT activation by direct binding to the calcineurin active site 6 . However, in yeast the RCAN1 homologue RCN1/CBP1 has functional and phenotypic characteristics of a calcineurin activator [7] [8] [9] . Consistent with this observation, Rcan1 -/-mice showed an impaired cardiac hypertrophic response to pressure overload or chronic adrenergic stimulation, suggesting that it may also function to enhance calcineurin-NFAT signalling in higher organisms 10, 11 . RCAN1 is also phosphorylated as a means of altering its effect on calcineurin 12 .
In this study, we identified TAK1-binding protein 2 (TAB2) as an RCAN1-interacting factor. TAB2 is an adaptor protein linking signals from the transforming growth factor-β (TGF-β) receptor and TRAF proteins to the TGF-β-activated kinase 1 (TAK1) signalling complex 13 . TAK1 is an upstream member of the mitogen-activated protein kinase (MAPK) superfamily, which functions as a pivotal integrator of membrane-bound signals elicited by TGF-β, interleukin-1 (IL-1), IL-18, tumour necrosis factor (TNF) and receptor activator of nuclear factor κB (NF-κB) ligands (RANKL) 14, 15 . TAK1 forms a complex with TAB2 and TAB1 (TAK1-binding protein 1), where TAB1 functions as an activator of TAK1 16 . The TAK1-TAB1-TAB2 complex directly activates MAPK kinase 3/6 (MKK3/6) and p38, MKK4 and c-Jun N-terminal kinase (JNK), as well as the NF-κB pathway 17, 18 . TAK1 signalling has also been shown to be essential in regulating a number of important biological processes, including the cardiac hypertrophic growth response 19 . The identification of RCAN1 as an interacting partner for the TAK1-TAB1-TAB2 complex suggests an interaction between two central regulatory pathways, which here we show serves to control the cardiomyocyte growth response.
Three independent RCAN1-interacting clones encoding amino acids 402-693 of mouse TAB2 were obtained from approximately 3.2 × 10 6 transformants. Re-transformation of RCAN1 bait with TAB2 prey gave a strong interaction that supported growth on selectable X-α-galactosidase medium in yeast, similar to a positive control consisting of TAK1 bait with a TAB2 prey plasmid (Fig. 1a) . No interaction was observed with RCAN1 bait alone, TAB2 prey alone or RCAN1 bait with either TAB1 or TAK1 prey (Fig. 1a) . The interaction with RCAN1 was also observed with just a carboxy-terminal fragment of TAB2, but not with the amino terminus (Fig. 1b) . These data suggest that RCAN1 interacts directly with TAB2, but not with other members of the TAK1 complex. To further characterize this interaction, a GST pulldown assay was performed with GST or GST-RCAN1 in combination with TAK1, TAB1 and TAB2 proteins (Fig. 1c) . This assay showed a direct interaction between RCAN1 and full-length TAB2 and the C terminus of TAB2, but not with GST alone (Fig. 1d) . TAB2 deletion fragments were also subjected to pulldown with GST-RCAN1 or GST alone (Fig. 1e, f) . GST-RCAN1, but not GST alone, interacted with full-length TAB2, TAB2 401-693 and TAB2 401-500. Equal content of GST-RCAN1 was shown by SDS-PAGE stained with Coomassie brilliant blue (Fig. 1f) . TAB2 amino acids 401-500 was the minimum fragment sufficient for RCAN1 binding (Fig. 1g) . In addition, a reciprocal pulldown assay was performed in which RCAN1 deletion proteins were radioactively labelled and subjected to pulldown with GST-TAB2 or GST alone (Fig. 1h, i) . Equal content of the GST-TAB2 fusion protein was also shown by SDS-PAGE (Fig. 1i ). The RCAN1 50-100 fragment was the minimum region for TAB2 interaction (Fig. 1j) .
To confirm that the association between RCAN1 and TAB2 occurs in mammalian cells, RCAN1, TAB2, TAK1 and TAB1 were overexpressed in neonatal cardiomyocytes by infection with corresponding recombinant adenoviruses, followed thereafter by immunoprecipitation with an anti-RCAN1 antibody. The results show that TAB2 was immunoprecipitated with an RCAN1 antibody but not with a non-specific IgG antibody (Fig. 2a) . Moreover, immunoprecipitation of RCAN1 resulted in the isolation of TAK1 and TAB1, suggesting that RCAN1 associates with the entire TAK1-TAB1-TAB2 complex (Fig. 2a) . Importantly, endogenous TAK1, TAB1 and TAB2 immunoprecipitated with RCAN1 in cardiomyocytes, although we needed to overexpress activated calcineurin (ΔCnA) as a way of inducing sufficient RCAN1 expression (Fig. 2b) . 
TAK1 phosphorylates RCAN1 at Ser 94 and Ser 136
As TAK1 is a kinase, we hypothesized that it may phosphorylate RCAN1 as a regulatory mechanism. To address this possibility, cardiomyocytes were infected with adenoviruses encoding RCAN1, TAK1 and its activator TAB1, constitutively active TAK1 (TAK1 ΔN ), or β-galactosidase as an internal control (Fig. 2c) . RCAN1 was then immunoprecipitated and analysed by western blotting with an anti-phospho-Ser antibody, showing RCAN1 phosphorylation by TAK1 (Fig. 2c) . This effect was directly assessed in vitro using a kinase assay with recombinant-purified RCAN1 and a purified active TAK1-TAB1 fusion protein. The data show strong autophosphorylation of TAK1 (Fig. 2c) and detectable phosphorylation of RCAN1 in the presence of TAK1-TAB1 (Fig. 2d) . Apoptosis signalregulating kinase 1 (ASK1), another MAPKKK, did not phosphorylate RCAN1, suggesting specificity for TAK1 (data not shown).
A previous study identified two Ser residues in RCAN1, Ser 108 and Ser 112, which were phosphorylated by glycogen synthase kinase 3β (GSK-3β) and MAPK, respectively 7, 20 . To determine whether these two Ser residues are also phosphorylated by TAK1, cardiomyocytes were infected with adenoviruses encoding TAK1 and its activator TAB1, TAK1 ΔN , or β-galactosidase along with RCAN1 S108/112A in which Ser 108 and Ser 112 were mutated to Ala (Fig. 2e) . Immunoprecipitation of RCAN1 S108/112A followed by western blotting with anti-phospho-Ser antibody showed no reduction in phosphorylation, suggesting that TAK1 phosphorylated RCAN1 elsewhere (Fig. 2e ). An in vitro kinase assay with purified RCAN1 S108/112A also showed phosphorylation by TAK1 (data not shown). Mass spectrometry was performed to identify the putative TAK1 phosphorylation sites in RCAN1, revealing sites at Ser 94 and Ser 136. Phosphorylation-specific rabbit polyclonal antibodies were then generated to the newly identified sites in RCAN1. Transfection of constructs mutated at Ser 94 or Ser 136, followed by western blotting showed that the antibodies were specific for their designated sites (Fig. 2f) . To determine whether RCAN1 is phosphorylated in vivo at Ser 94 and Ser 136, western blotting was performed on cardiomyocyte extracts after infection with RCAN1 adenovirus and treatment with serum, TGF-β, phenylephrine (PE), angiotensin II (Ang II) or endothelin-1 (ET-1). Each of the agonists produced detectable RCAN1 phosphorylation at both sites, but TGF-β gave the most robust effect, especially at Ser 136 (Fig. 2g) . We also wanted to determine whether TAK1-mediated phosphorylation of RCAN1 depended on formation of the greater complex through TAB2. Remarkably, phosphorylation of endogenous RCAN1 at both Ser 94 and Ser 136 was blocked in Tab2 -/-MEFs but not in wild-type MEFs (Fig. 2h ).
TAK1 activates calcineurin-NFAT signalling through RCAN1
As will be presented below, TAK1 activation promotes a marked increase in calcineurin-NFAT activity through RCAN1. This feature of TAK1 was used to further probe the necessity of TAB2 in mediating a physiological response of TAK1 to calcineurin-NFAT. For example, NFAT-luciferase activity was stimulated by TGF-β, serum, TAK1+TAB1 or TAK1 ΔN in wild-type MEFs, but this activation was markedly reduced in Tab2 -/-MEFs, whereas activated calcineurin still increased NFAT activity in both cell lines (Fig. 2i, j) . Similarly, TGFβ-induced NFAT-luciferase reporter activity was blocked in Tak1 -/-MEFs ( Supplementary Information,  Fig. S1a ). These results suggest that TAK1 regulates endogenous calcineurin-NFAT signalling by forming a complex through TAB2, permitting phosphorylation of RCAN1 at Ser 94 and Ser 136.
To begin to examine the functional relevance of RCAN1 phosphorylation by TAK1, we examined calcineurin-NFAT activity in cultured neonatal cardiomyocytes in greater detail, as well as the hypertrophic growth response. Cardiomyocytes were infected with adenoviruses encoding an NFAT-luciferase reporter cassette, TAK1 and its activator TAB1, or TAK1 ΔN . TAK1 activated the NFAT-luciferase reporter by more than 50-fold (P < 0.05) in cardiomyocytes, an effect that was largely reversed by co-infection with AdCain, a calcineurin inhibitor ( Fig. 3a) . Similar infections were performed in cardiomyocytes with an adenovirus encoding NFATc1-GFP. Western blotting for NFATc1 was then performed to monitor phosphorylation differences (Fig. 3b) .
As with activated calcineurin (ΔCnA), TAK1 enhanced NFATc1 dephosphorylation, resulting in increased migration on SDS-PAGE. Collectively, these data indicate that TAK1 activates NFAT transcriptional activity through a calcineurin-dependent mechanism. Conversely, infection with a dominant-negative TAK1 KW adenovirus inhibited baseline NFAT-luciferase activity, suggesting that endogenous TAK1 regulates basal calcineurin-NFAT signalling (Fig. 3c) . TAK1-TAB1 or TAK1
ΔN augmented, whereas dominant-negative TAK1 KW diminished ΔCnA-induced NFAT-luciferase activity, further supporting the notion that TAK1 acts as a positive regulator of calcineurin-NFAT activity in cardiomyocytes (Fig. 3c) . Similar results were also observed in Jurkat T cells (Fig. 3d) .
RCAN1 functions as an inhibitor of calcineurin when overexpressed 21, 22 , consistent with our observations that both baseline and ΔCnA-induced NFAT-luciferase activity are inhibited by RCAN1 overexpression in a concentration-dependent manner (Fig. 3e) . However, co-infection of AdTAK1 with AdTAB1 produced an entirely different pattern of NFAT activity (Fig. 3e) . Indeed, low concentrations of RCAN1 facilitated calcineurin-NFAT signalling in the presence of TAK1+TAB1 KW adenoviruses and stimulated with PE (50 μM), 1% FBS, or TGF-β (5 ng ml -1 ). Data are mean ± s.e.m. of three independent experiments (*P < 0.001 versus control; #P < 0.001 versus Adβ-gal for each stimulant). (h) Cardiomyocyte surface areas after infection with β-gal or TAK1 KW adenoviruses with or without PE, 1% FBS or TGF-β stimulation for 24 h. Data are mean ± s.e.m. of three independent experiments (*P < 0.001 versus Control; #P < 0.001 versus Adβ-gal of each stimulant). (i) Cardiomyocyte surface areas after infection with Adβ-gal or an adenovirus expressing RCAN1 amino acids 50-100. Twenty-four hours later cells were stimulated with PE, 1% FBS, TGF-β, or infected with adenoviruses encoding TAK1+TAB1 for another 24 h. Data are mean ± s.e.m. of three independent experiments (*P < 0.001 versus Control; #P < 0.001 versus Adβ-gal of each stimulant). See Supplementary  Information, Fig. S3 for full scans of westerns.
( Fig. 3e) , suggesting that TAK1 augments calcineurin-NFAT signalling through RCAN1. Mutation of the TAK1 phosphosphorylation sites in RCAN1 to Asp led to increased NFAT transcriptional activity, whereas mutation of both sites to Ala inhibited NFAT activity (Fig. 3f) . More importantly, TAK1 was no longer able to activate calcineurin-NFAT signalling in Rcan1/2 -/-MEF cultures, whereas wild-type MEFs show robust activation of the AdNFAT-luciferase reporter with co-infection of AdTAK1 + AdTAB1 or with AdTAK1 ΔN (Fig. 3g, h ; Supplementary  Information, Fig. S1b ). However, Rcan1/2 -/-MEFs were more responsive to NFAT activation by an adenovirus encoding activated calcineurin than wild-type MEFs (Fig. 3g, h) . Finally, the known augmentation in NFAT activity by RCAN1 S94/136D overexpression was not enhanced by TAK1 in Rcan1/2 -/-MEFs, indicating that TAK1 specifically regulates calcineurin-NFAT signalling only through these two amino acids in RCAN1 (Fig. 3i) . Collectively, these results indicate that TAK1-induced NFAT activation occurs entirely through its interaction with, and phosphorylation of, RCAN1.
A series of biochemical and cellular assays were performed to further examine the functional ramifications associated with the TAK1-TAB1-TAB2 and RCAN1-calcineurin-NFAT complex. Consistent with the GST pulldown assay described above, immunoprecipitation with several RCAN1 deletions showed that amino acids 50-100 of RCAN1 is sufficient to bind TAB2 and TAK1 in HEK293 cells (Fig. 4a) . However, a different domain of RCAN1 (amino acids 150-198) was required for calcineurin association (Fig. 4a) . These two deletion mutants were used to more carefully examine the effect of TAK1 on NFAT activation in vivo. Interestingly, both RCAN1 1-150 and RCAN1 50-100, which lack the calcineurininteracting domain, repressed NFAT activation induced by TAK1 + TAB1, whereas wild-type RCAN1 augmented NFAT activity (Fig. 4b) . However, neither deletion mutant of RCAN1 altered the ability of activated calcineurin to induce NFAT, but wild-type RCAN1 was still fully inhibitory (Fig. 4b) . These results further suggest that TAK1 regulates calcineurin-NFAT signalling through an RCAN1 dependent mechanism.
Although the stability of the calcineurin-RCAN1 complex is not affected by TAK1 (data not shown), loss of RCAN1 prevents TAK1 participation in the calcineurin-NFAT complex. For example, TAK1 immunoprecipitated with calcineurin in wild-type MEFs but not in Rcan1/2 -/-MEFs (Fig. 4c) . Furthermore, TAK1 co-immunoprecipitated with calcineurin in cardiomyocytes infected with fulllength AdRCAN1, but not with AdRCAN1 1-150, which lacks the calcineurin-interacting domain (Fig. 4d) . Collectively, these results indicate that RCAN1 serves as an adaptor for the formation of the entire macromolecular signalling complex.
TAK1 regulates cardiomyocyte hypertrophy through calcineurin-NFAT
To examine the functional consequences of TAK1 regulation of calcineurin-NFAT signalling, we used a growth assay in cultured neonatal cardiomyocytes, given that both calcineurin and TAK1 are known regulators of this process 3, 19 . TAK1 + TAB1 or TAK1 ΔN promoted NFATc1 nuclear translocation in cardiomyocytes, which was blocked with Cain (Fig. 4e) . More importantly, overexpression of TAK1 + TAB1 or TAK1 ΔN enhanced the growth response of cardiomyocytes in culture in a calcineurin-dependent manner, given inhibition by Cain (Fig. 4f) . Conversely, adenoviral-mediated overexpression of TAK1 KW reduced NFAT-luciferase activity and myocyte growth in response to PE, serum and TGF-β, indicating that TAK1 is a necessary mediator of myocyte hypertrophy in culture in association with NFAT activation (Fig. 4g, h) . Overexpression of an RCAN1 decoy mutant (amino acids 50-100), which binds TAB2-TAK1 but not calcineurin, inhibited agonist-and TAK1-induced hypertrophy of cardiac myocytes (Fig. 4i) . Finally, transfection of an RNAi against TAK1, but not a control RNAi, blocked agonist-induced hypertrophy in neonatal cardiomyocyte cultures ( Supplementary Information, Fig. S2a, b) . These results further support the importance of the TAK1-TAB1-TAB2 interaction with RCAN1-calcineurin-NFAT in controlling a crucial biologic response in vivo.
Calcineurin dephosphorylates and inactivates TAK1 and TAB1
We also investigated the reciprocal regulatory relationship to determine whether calcineurin might impart some type of regulation on TAK1. Cardiomyocytes were co-infected with adenoviruses expressing different combinations of activated calcineurin A and calcineurin B with TAK1 and TAB1, followed by western blotting for phospho-TAK1 at Thr 187, or total phosphorylation of TAB1, using an immunoprecipitation assay with anti-phospho-Ser/Thr antibodies (Fig. 5a) . The results show a marked reduction in TAK1-Thr 187 phosphorylation in the presence of ΔCnA/B, whereas TAB1 is completely dephosphorylated (Fig. 5a) . Conversely, TAK1+TAB1-induced autophosphorylation of TAK1 at Thr 187 was enhanced in calcineurin-deficient MEFs (lacking CnB1), suggesting that calcineurin basally regulates TAK1 phosphorylation (Fig. 5b) . Consistent with our earlier results, the calcineurin-dependent dephosphorylation of TAK1 and TAB1 was completely inhibited in Rcan1/2 -/-MEFs, whereas wild-type MEFs showed dephosphorylation comparable to that observed in cardiomyocytes (Fig. 5c) . These results indicate that RCAN1 is required for calcineurin-dependent dephosphorylation of the TAK1 complex. Finally, we also observed that calcineurindependent dephosphorylation of the TAK1-TAB1 complex reduced TAK1 kinase activity against MKK6 (Fig. 5d) . Similarly, TAK1 kinase activity towards MKK6 was increased in Rcan1/2 -/-MEFs, compared with wild-type MEFs, after a time course of TGF-β stimulation, suggesting that endogenous calcineurin normally participates in TAK1 inactivation (Fig. 5e) . The total amount of TAK1 immunoprecipitated in the kinase assay was the same under each condition (Fig. 5e) . Collectively, the results in this section indicate that calcineurin can directly antagonize TAK1 signalling, suggesting a self-limiting feedback loop (Fig. 5f ).
DISCUSSION
Here we have shown that TAB2 interacts directly with RCAN1 in mammalian cells, generating a higher-order complex between the TAK1-TAB1-TAB2 and the RCAN1-calcienurin-NFAT signalling modules. This interaction produced two independent regulatory effects, the first of which was a TAK1-dependent phosphorylation of RCAN1, resulting in greater calcineurin-NFAT coupling, greater NFAT-dependent gene activation and hypertrophy in neonatal cardiomyocytes. This result suggests that the TAK1-TAB1-TAB2 signalling module promotes the cardiac growth response through enhancement of calcineurin-NFAT signalling, although TAK1-TAB1-TAB2 signalling probably affects the growth response through other effectors as well, such as NF-κB (Fig. 5e) . Indeed, TAK1 overexpression in the heart induces the cardiac growth response, indicating that it functions as a central regulator of this process 19, 23 . Our results further establish the importance of TAK1, showing that it is both sufficient and necessary for cardiomyocyte hypertrophic growth through an RCAN1-calcineurin signalling mechanism. Conversely, activation of calcineurin dampens TAK1 signalling through calcineurin-dependent dephosphorylation of both TAK1 and TAB1. This latter observation suggests that calcium signals that mobilize calcineurin, secondarily modulate TGFβ, TLR and IL1R signals. However, signals that initiate TAK1 activation may or may not produce a negative-feedback loop to dampen TAK1 signalling through RCAN-calcineurin. More specifically, we have only shown that RCAN1 facilitates NFAT activity downstream of calcineurin, presumably by enhancing coupling, as previously shown 10 ( Fig. 3) . Thus, when TAK1 phosphorylates RCAN1 resulting in greater calcineurin-NFAT coupling, it is uncertain whether this also results in calcineurin dephosphorylation of NFAT-independent targets, such as TAB1 or TAK1.
Our data indicate that the effect of RCAN1 on calcineurin signalling depends on both post-translational modifications (that is, phosphorylation) and the expression level of RCAN1. At low TAK1 activity, dephosphorylated RCAN1 inhibits calcineurin activity by binding to the regulatory site on calcineurin, thus blocking NFAT activation. At high TAK1 activity RCAN1 is predominantly phosphorylated, causing a change in its function towards calcineurin such that it now facilitates activation of NFAT. When RCAN1 is overexpressed at low to intermediate levels, TAK1 can still enhance calcineurin-NFAT coupling through RCAN1. However, when RCAN1 is overexpressed at very high levels, it acts as an inhibitor, probably through a non-physiological blocking mechanism. It remains uncertain exactly how RCAN1 facilitates calcineurin-NFAT signalling, although inhibitor-2 and DARPP-32 may have a similar role in permitting PP1 activity 24, 25 . Specifically, phosphorylation and dephosphorylation can cause conformational changes in inhibitor-2 that allosterically regulates PP1 activity 26 .
Here we showed that TAK1 directly phosphorylated RCAN1 at two sites (Ser 94 and Ser 136), resulting in activation of calcineurin-NFAT signalling. Two other groups reported that RCAN1 is also phosphorylated at Ser 108 and Ser 112, although they disagreed on the functional effect associated with this event. Genesca et al. 12 reported that phosphorylation of Ser 108 and 112 increased the inhibitory capacity of RCAN1 towards calcineurin-NFAT. In contrast, Abbasi and colleagues 27 demonstrated that phosphorylated RCAN1 dissociates from calcineurin and binds with 14-3-3, thereby relieving its inhibitory effect. In vivo, deletion of Rcan1/2 genes produced phenotypic effects that mimicked a loss of calcineurin signalling capacity, suggesting that the net biological function of RCANs in vivo is to facilitate calcineurin-NFAT signalling 10, 11 . Thus, the physiological effect of TAK1 on calcineurin-NFAT signalling at endogenous levels of RCAN1 expression is most certainly supportive in effect. These results suggest an entirely different signalling circuit whereby two major regulatory pathways interact to control at least one biological response, cardiomyocyte growth.
METHODS
Yeast two-hybrid assay. Yeast two-hybrid screening was performed using the Matchmaker Gal4 two-hybrid System 3 (Clontech) as described previously 28 . The bait construct consisted of full-length murine RCAN1 cloned in-frame into the plasmid pGBKT7. Yeast strain AH109 was co-transformed with the bait and a murine adult cardiac cDNA library constructed into the EcoRI site of pGAD10 (custom-made library; Clontech).
Cell culture. Primary neonatal rat cardiomyocytes were prepared from hearts of 1-2-day-old Sprague-Dawley rat pups as described previously 28 . Rcan1/2 -/-or wild-type MEFs were isolated at embryonic day 12.5 by trypsin digestion, as described previously 10 . HEK293 cells were purchased from American Cell Culture Collection and cultured as previously described 28 .
Tab2
-/-and Tak1 -/-MEFs were gifts from Shizuo Akira (Osaka University, Japan). Cells were transfected with Fugene-6 reagent (Roche Applied Sciences). Adenoviral infections were performed as described previously at a multiplicity of infection of 10-100 plaque forming units per ml 28 . Cultures were collected 24 h after infection and luciferase assays were preformed as described previously 29 . Adenoviral constructs and expression vectors. Adβgal, AdΔCnA, AdCnB, AdCain, AdNFAT-Luc and AdNFATc1-GFP have been described previously 28 . S94D and RCAN1 S94/136D were generated using the QuickChange site-directed mutagenesis kit (Stratagene).
GST pulldown assays. To generate GST fusion proteins, selected DNA sequences from TAB2 and RCAN1 were amplified by PCR and subcloned into pGEX-4T-1 (Amersham Pharmacia Biotech). Binding assays were performed with 35 S-methionine-labelled proteins synthesized in vitro using a transcription-translation-coupled reticulocyte lysate system (Promega) as described previously 28 .
Immunoprecipitation and western blot analysis. Immunoprecipitation was performed as described previously 28 . Proteins were resolved on 8-15% SDS-PAGE gels, transferred to PVDF membranes and immunoblotted using the following antibodies: anti-TAK1, anti-TAB1, anti-TAB2 and anti-pan CnA (Santa Cruz Biotechnology); anti-phospho Ser (Chemicon International); anti-FLAG (Sigma); anti-Myc-Tag, anti-phospho-TAK1(Thr 187), anti-phosphothreonine (Cell Signalling). Custom rabbit polyclonal anti-phospho-RCAN1-Ser 136 and anti-phospho-RCAN1 Ser 94 were generated and affinity purified by YenZym.
Immunoprecipitation kinase assay. TAK1 was immunoprecipitated with anti-TAK1 (Santa Cruz Biotechnology) and protein A/G-agarose. After washing the immunoprecipitates three times with lysis buffer 28 and once with kinase assay buffer (20 mM Tris-Cl, pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride), the immunoprecipitates were incubated with GST-MKK6 (1 μg) in 25 μl of kinase assay buffer containing 0.3 μCi of 32 P-ATP for 10 min at 30°C. Samples were subjected to SDS-PAGE (8%) and visualized by PhosphorImager analysis (Amersham Pharmacia Biotech).
Immunohistochemistry and hypertrophy analysis. To assess cardiomyocyte hypertrophy, cells were immunostained with an antibody against α-actinin (Sigma). Quantification of cardiomyocyte cell surface area was performed on α-actinin-stained cardiomyocytes by confocal laser microscopy and NIH Image Analysis software, version 1.63.
Detection of phosphorylation sites by mass spectrometry. Purified RCAN1 was incubated with the purified TAK-TAB1 fusion protein (Upstate Biotechnology) in reaction buffer with or without ATP at 30°C for 15 min. The samples were digested with trypsin overnight. An aliquot of each digest was analysed using nanoflow-HPLC electrospray ionization directly coupled to an LTQ-Orbitrap (Thermo Electron) using top 5 data-dependent mode MS/MS mode as previously described 30 . All MS/MS spectra were searched with Sequest using variable modification of +80 on Ser and Thr for identification of phosphorylation. Data were loaded into Scaffold (Proteome Software) for manual validation. 
